Business Wire

New ISACA Guide Outlines Key Components of Digital Trust Implementation

4.5.2022 16:30:00 EEST | Business Wire | Press release

Share

While we may not always realize it, most of our interactions as consumers create a digital footprint—whether we are paying a friend through a mobile app or registering online for a doctor’s appointment. But can we always trust that our transactions and interactions in these digital ecosystems will be conducted with integrity? A new complimentary white paper from ISACA, Digital Trust: A Modern-Day Imperative, explores this increasingly important concept of digital trust, how it relates to both consumers and providers, and how it works in practice.

Digital Trust provides a detailed definition of digital trust—the confidence in the integrity of the relationships, interactions and transactions among suppliers/providers and customers/consumers within an associated digital ecosystem—and examines how imperative it is for enterprises to build and maintain this trust.

The paper, launched at the ISACA Conference North America today, is the first resource in ISACA’s new digital trust strategy.

“Think about a digital space with fewer attacks, more innovation and business growth, and enhanced confidence, with IT professionals leading the way,” said ISACA CEO David Samuelson. “Our global community of like-minded IT professionals works in pursuit of digital trust. More trust means more success. And as security, privacy, assurance and quality professionals, the ISACA community is a key enabler of that success.”

The Digital Trust paper outlines how consumers consider six key elements when assessing digital trust:

  1. Quality
  2. Availability
  3. Security and privacy
  4. Ethics and integrity
  5. Transparency and honesty
  6. Stability and resilience

Many enterprises already realize that valuing digital trust provides them with a competitive advantage, both with their reputation and bottom line. Digital Trust outlines some of the ways that providers can put digital trust in practice, including:

  • Refraining from using dark patterns or techniques to trick or influence data subjects to make a specific choice
  • Conducting regular audits to ensure that controls are in place and working as they should
  • Providing employees with trustworthy technology to do their jobs, and not monitoring them without their knowledge or consent.

“It is absolutely critical for digital trust to be woven into the fabric of any enterprise—to avoid harmful security and privacy incidents, strengthen relationships with consumers, and advance reputation and the bottom line,” says Mark Thomas, president, Escoute Consulting. “Professionals who work in security, audit, governance, risk or privacy all play an essential role in driving digital trust forward, so it is vital that each understands their part in establishing, evaluating, adjusting and implementing digital trust practices within their organizations.”

To download a complimentary copy of the white paper, visit www.isaca.org/digital-trust. ISACA will release additional digital trust resources later this year, including a course, webinar, global research and digital trust framework.

Additional information on ISACA’s digital trust strategy is available in this ISACA Now blog post from ISACA CEO David Samuelson here.

About ISACA

For more than 50 years, ISACA® (www.isaca.org) has equipped individuals with knowledge, credentials, education and community to progress their careers and transform their organizations, and enabled enterprises to train and build quality teams. A global professional association and learning organization, ISACA leverages the expertise of its more than 150,000 members who work in information security, governance, assurance, risk and privacy to drive innovation through technology. It has a presence in 188 countries, including more than 220 chapters worldwide. In 2020, ISACA launched One In Tech, a philanthropic foundation.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Emily Van Camp, evcamp@isaca.org, +1.847.385.7223
Kristen Kessinger, communications@isaca.org, +1.847.660.5512

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release

Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This

IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 13:38:00 EEST | Press release

For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will

Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital18.9.2026 12:48:00 EEST | Press release

Estithmar Holding Q.P.S.C. announced the completion of the transfer of a 48.68% stake in Shahba Bank to Masaref Holding LLC, subsidiary of Estithmar Capital, Estithmar Holding’s financial services and investments arm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918807909/en/ Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital (Photo: AETOSWire) As a shareholder, Masaref Holding intends to support the assessment of proposals aimed at strengthening Shahba Bank’s financial, operational and technological capabilities, including potential capital enhancement, branch network expansion, and the development of products and services for individuals, businesses and SMEs. The proposals may include modernizing banking and operational systems, develop digital services, and strengthen governance, compliance, risk management and cybersecurity to enhance

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye